What is Iterum Therapeutics Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Iterum Therapeutics's annualizedGross Profit for the quarter that ended in Sep. 2024 was $0.00 Mil.
Iterum Therapeutics's average Total Assets over the quarter that ended in Sep. 2024 was $15.05 Mil. Therefore, Iterum Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 0.00%.
Iterum Therapeutics Gross-Profit-to-Asset % Historical Data
The historical data trend for Iterum Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Iterum Therapeutics's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Iterum Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's Gross-Profit-to-Asset % falls into.
Iterum Therapeutics Gross-Profit-to-Asset % Calculation
Iterum Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Sep. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Iterum Therapeutics Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Iterum Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ITRM has been successfully added to your 